超越生育力保存:肿瘤生育单元在年轻癌症患者生殖与妇科随访中的作用
该回顾性研究分析了2012年1月至2017年6月期间154例18-40岁年轻女性癌症患者,在抗癌治疗前接受肿瘤生育咨询后返回随访的比例与原因。48.1%患者返回随访,首次随访主要发生在抗癌治疗结束时(51.3%),仅10.8%因积极希望妊娠而返回,最常见原因为评估卵巢储备(39.2%)和管理妇科不良反应(29.7%)。作者认为肿瘤生育单元的作用不应仅限于提供生育力保存。
要点
- 154例年轻女性癌症患者中74例(48.1%)返回肿瘤生育单元随访。
- 首次随访多因评估卵巢储备(39.2%)或管理妇科不良反应(29.7%),仅10.8%因希望妊娠。
- 所考察因素均未显著预测返回随访。
核心结论
- 肿瘤生育单元的作用不应仅限于提出生育力保存方案。
- 在年轻成人癌症患者管理中,生殖医学专家应被视为抗癌治疗前、治疗期间及治疗后的关键人物,以探讨妇科与生殖健康的重要方面。
研究设计与样本
- 回顾性研究,纳入154例连续年轻女性癌症患者(年龄范围18-40岁),于2012年1月至2017年6月期间接受治疗前咨询。
- 收集人口学与临床数据,以及所选生育力保存方法(若有)的信息。
- 随访率与原因以百分比表示,并在全队列及按恶性肿瘤类型分层分析。
- 通过逻辑回归探究返回随访的可能预测因素(年龄、未产、有伴侣、肿瘤、是否冻存材料)。
主要发现
- 154例患者中74例(48.1%)返回肿瘤生育单元随访。
- 首次随访主要请求于抗癌治疗结束时(51.3%),治疗期间为40.5%,癌症复发后为8.1%。
- 仅10.8%患者首次返回是因为积极希望妊娠。
- 其他常见咨询原因为管理治疗的妇科不良反应(29.7%)和与近期无妊娠意愿无关的卵巢储备评估(39.2%)。
- 其他患者要求避孕(4.1%)、绝经咨询(5.4%)或因癌症复发进行新的生育力保存咨询(10.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现代表单中心的经验。
- 需要更长的随访时间以提供更精确的信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are there reasons that motivate young cancer survivors to ask for follow-up visits at an oncofertility unit? SUMMARY ANSWER: Cancer survivors request oncofertility follow-up visits for the management of treatment-related side effects or ovarian reserve evaluation, even if not (or not yet) wishing for a pregnancy. WHAT IS KNOWN ALREADY: Personalised oncofertility counselling before gonadotoxic therapies is considered standard of care for young women with newly diagnosed cancer. However, the long-term follow-up of these patients in an oncofertility unit is not described in the literature other than for the use of cryopreserved material. STUDY DESIGN, SIZE, DURATION: We retrospectively examined rates and reasons for the first follow-up visits of 154 consecutive young female cancer patients (age range: 18-40 years) who underwent a pre-treatment consultation between January 2012 and June 2017. Demographic and clinical data were collected, as well as information about the chosen fertility preservation method, if any. PARTICIPANTS/MATERIALS, SETTING, METHODS: Rates and reasons for follow-up visits were collected and expressed as percentages. Different reasons were examined in the whole cohort and stratified for type of malignancy. Possible predictive factors for return to the follow-up visit (age, nulliparity, presence of a partner, neoplasm, having cryopreserved material) were investigated through logistic regression. MAIN RESULTS AND THE ROLE OF CHANCE: Out of 154 patients, 74 returned to the oncofertility unit (48.1%) for a follow-up visit. The first visit was requested mostly at the end of anticancer therapies (51.3% versus 40.5% during therapies and 8.1% after cancer relapse). Among these patients, only 10.8% returned for the first time because they were actively desiring a pregnancy. For the others, the most common reasons for consultations were management of gynecological adverse effects of therapies (29.7%) and evaluation of ovarian reserve not linked to an immediate desire for a pregnancy (39.2%). Other patients asked for contraception (4.1%), menopause counselling (5.4%), or new fertility preservation counselling because of cancer relapse (10.8%). None of the examined factors were significantly predictive of return to the oncofertility unit. LIMITATIONS, REASONS FOR CAUTION: These findings represent the experience of a single centre. A longer duration of follow-up would be needed to provide more precise information on this regard. WIDER IMPLICATION OF THE FINDINGS: The role of an oncofertility unit should not be limited to proposing fertility preservation procedures. In the management of young adult cancer patients, the reproductive medical specialist should be considered a key figure not only before but also during and after anticancer treatments to explore salient aspects of gynecological and reproductive health. STUDY FUNDING/COMPETING INTEREST(S): This research did not receive any specific funding. M.L. served as a consultant for Teva and received honoraria from Theramex outside the submitted work. The other authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N.A.
引用
- Massarotti C, Scaruffi P, Lambertini M, et al. Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients. Hum Reprod. 2019. PMID: 31339999. doi:10.1093/humrep/dez108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。